Amgen’s Otezla bags expanded FDA nod in psoriasis; I-Mab CEO hits the exit amid shakeup at Chinese firm

Just a few weeks after Otezla notched a Phase III win and hit all primary and secondary endpoints for a trial in genital psoriasis, Amgen’s blockbuster drug Otezla gets yet another OK from the FDA.

The biotech announced this morning the FDA approved Otezla (apremilast) for an...

Click to view original post